The UK and US have concluded a key bilateral deal that will keep zero levies on UK pharmaceutical shipments going into the American market.
The Terms of the Deal
As part of the deal, the UK has committed to boost expenditure on drugs through the public health system. This commitment secures that import taxes on these vital exports will be held at zero for a duration of the next three years.
This development follows recent statements to hike tariffs on branded drug products, with potential rates mentioned reaching 100%.
"This deal with the United Kingdom strengthens the international landscape for new treatments and introduces long-overdue equity to U.S.–U.K. pharmaceutical trade," an announcement declared.
Economic Impact
Drugs are one of the UK's biggest export categories to the US, which is easily the largest buyer for leading companies like GSK and AstraZeneca.
Statistics show that in the one-year period prior to September, the UK sold drugs valued at billions to the US. This value represented nearly one-fifth of total UK exports in that span.
"This guarantee safeguards jobs, increases funding and sets the stage for the UK to establish itself as a international leader for medical research," a government official remarked.
Specific UK Commitments
The agreement involves several key changes from the British government:
- Revised Affordability Limit: The UK will increase the price threshold at which it considers new treatments to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a target to raise overall public funding on treatments from 0.3% of GDP to 0.6 percent over the next decade.
- Payback Limit: The percentage pharmaceutical firms must return to the NHS to prevent overspending will be limited at fifteen percent. Last year, rebates were more than twenty percent.
Broader Context
The pact follows a protracted row between the sector and the UK government over drug pricing and regulatory access.
These tensions were exacerbated by claims that US customers were paying significantly more for the identical medicines than patients in the UK and Europe.
In recent months, several significant drug company projects in the UK have been delayed or abandoned, while major funding commitments have been directed toward projects in the United States.
A senior figure acknowledged that the NHS had to spend more on treatments, noting that its spending on drugs had decreased as a proportion of its total funding over the previous ten-year period.
